SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in VolitionRx Ltd

Armistice Capital, LLC and Steven Boyd have disclosed a combined beneficial ownership of 9.99% of VolitionRx Ltd.'s common stock, totaling 9,804,352 shares, as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in VOLITIONRX LTD.
• The Reporting Persons collectively beneficially own 9,804,352 shares of Common Stock, par value $0.001 per share, of VOLITIONRX LTD.
• This ownership represents 9.99% of the issuer's outstanding class of securities.
• Both Armistice Capital, LLC and Steven Boyd hold shared voting power and shared dispositive power over all 9,804,352 shares.
• Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares, and exercises voting and investment power over these securities.
• Steven Boyd is identified as the managing member of Armistice Capital, LLC.
• The Reporting Persons certify that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently suggest positive or negative sentiment regarding the company's performance or prospects. The certification explicitly states the shares are held for passive investment purposes.

Future Outlook

NA

Industry Context

This filing is a standard disclosure required by the U.S. Securities and Exchange Commission (SEC) when an entity or individual acquires beneficial ownership exceeding 5% of a company's outstanding shares. It indicates a significant, but passive, investment by Armistice Capital and Steven Boyd in VolitionRx Ltd. Such disclosures are common among institutional investors and hedge funds, providing transparency on major shareholdings within the market.

Related Party Transactions

• Armistice Capital, LLC, as the investment manager, exercises control over the shares held by Armistice Capital Master Fund Ltd., which is an investment advisory client of Armistice Capital. The Master Fund has the right to receive dividends and proceeds from the sale of these securities.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.

Key Dates

Keywords

VOLITIONRX LTD, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing, Institutional Investor, Shareholding